Evidence map›Paper›PMID 24098381›Full record

ArticlePloS one2013

DNA damage repair genes controlling human papillomavirus (HPV) episome levels under conditions of stability and extreme instability.

Terri G Edwards, Thomas J Vidmar, Kevin Koeller, James K Bashkin, Chris Fisher

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Targeting DNA Damage Response as a Strategy to Treat HPV Infections.International journal of molecular sciences · 2019
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. [Recognition study of double strand DNA with hairpin oligopolyamide].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2017
    Article
  17. Synthetic genome readers target clustered binding sites across diverse chromatin states.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Terri G EdwardsNanoVir, Kalamazoo, Michigan, United States of America.
Thomas J Vidmar
Kevin Koeller
James K Bashkin
Chris Fisher
Michigan United · USNanoVir (United States) · USUniversity of Missouri–St. Louis · US

Funding

Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human PaR42AI068159 · NIAID · NANOVIR, LLC. · PI FISHER, CHRISTOPHER · 2010 to 2012
$3.0M
Pre-Clinical HPV16 Antiviral Compound DevelopmentR42AI062182 · NIAID · NANOVIR, LLC. · PI FISHER, CHRISTOPHER · 2008 to 2010
$2.9M
Biophysics of Drug Interactions with Viral EpisomesR01AI083803 · NIAID · UNIVERSITY OF MISSOURI-ST. LOUIS · PI BASHKIN, JAMES K. · 2010 to 2014
$1.8M
Antiviral Compounds that Target HPV18 DNAR41AI068159 · NIAID · NANOVIR, LLC. · PI FISHER, CHRISTOPHER · 2007 to 2008
$979k
Antiviral Compounds for Human Papillomavirus 16R41AI062182 · NIAID · NANOVIR, LLC. · PI FISHER, CHRISTOPHER · 2004 to 2005
$771k
NIAID NIH HHS AI062182NIAID NIH HHS AI068159NIAID NIH HHS AI083803NIAID NIH HHS R01 AI083803NIAID NIH HHS R41 AI062182NIAID NIH HHS R41 AI068159NIAID NIH HHS R42 AI062182NIAID NIH HHS R42 AI068159
6 · The paper itself

Abstract

DNA damage response (DDR) genes and pathways controlling the stability of HPV episomal DNA are reported here. We set out to understand the mechanism by which a DNA-binding, N-methylpyrrole-imidazole hairpin polyamide (PA25) acts to cause the dramatic loss of HPV DNA from cells. Southern blots revealed that PA25 alters HPV episomes within 5 hours of treatment. Gene expression arrays identified numerous DDR genes that were specifically altered in HPV16 episome-containing cells (W12E) by PA25, but not in HPV-negative (C33A) cells or in cells with integrated HPV16 (SiHa). A siRNA screen of 240 DDR genes was then conducted to identify enhancers and repressors of PA25 activity. Serendipitously, the screen also identified many novel genes, such as TDP1 and TDP2, regulating normal HPV episome stability. MRN and 9-1-1 complexes emerged as important for PA25-mediated episome destruction and were selected for follow-up studies. Mre11, along with other homologous recombination and dsDNA break repair genes, was among the highly significant PA25 repressors. The Mre11 inhibitor Mirin was found to sensitize HPV episomes to PA25 resulting in a ∼5-fold reduction of the PA25 IC50. A novel assay that couples end-labeling of DNA to Q-PCR showed that PA25 causes strand breaks within HPV DNA, and that Mirin greatly enhances this activity. The 9-1-1 complex member Rad9, a representative PA25 enhancer, was transiently phosphorylated in response to PA25 treatment suggesting that it has a role in detecting and signaling episome damage by PA25 to the cell. These results establish that DNA-targeted compounds enter cells and specifically target the HPV episome. This action leads to the activation of numerous DDR pathways and the massive elimination of episomal DNA from cells. Our findings demonstrate that viral episomes can be targeted for elimination from cells by minor groove binding agents, and implicate DDR pathways as important mediators of this process.

Indexed as

AlphapapillomavirusCell LineDNA DamageDNA RepairDNA, ViralGene Knockdown TechniquesGenes, ViralHumansImidazolesKeratinocytesPlasmidsRNA, Small InterferingDNA, ViralImidazolesRNA, Small Interfering

Identifiers

PMID24098381
PMCPMC3788802
OpenAlexW2156547418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.